Working to Eradicate Gynecologic Cancers

Thomas J. Herzog, MD

Clinical Director
University of Cincinnati
3255 Eden Avenue
Suite 250B, ML 0662
Cincinnati, OH
USA 45267

Papers:
444 A state by state analysis of BRCA1 and BRCA2 testing in patients with ovarian cancer 509 PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy Ovarian cancer clinical trial endpoints A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian